Amicus presents new long-term data for Galafold, Pombiliti+ Opfolda

Amicus (FOLD) Therapeutics announced the presentation of new data from clinical and real-world studies of Galafold in Fabry disease and Pombiliti+ Opfolda in late-onset Pompe disease. Data are being presented at the 22nd Annual WORLDSymposium 2026. “Amicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our medicines at this year’s WORLDSymposium. These new data add to the growing body of evidence supporting the important role of Galafold and Pombiliti + Opfolda,” said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics. “We are immensely grateful to the patients, their families, and investigators whose partnership makes scientific research and advances possible.”